

Scottish Dry Eye Guidelines

VERSION 1.1

September 2018

Contents

Contents	1
Introduction	1
Dry Eye Working Group	1
Contributors to Dry Eye Working Group	1
Abbreviations	1
Overview of Guidelines	2
Dry eye assessment strategy	2 2 2 2 3
Dry eye treatment strategy	2
Proposed combined formulary	2
Dry Eye Assessment Strategy	3
Dry Eye Treatment Strategy	3
Bibliography	4
Appendix 1	4
Oxford Grading Scheme	4
Appendix 2	4
Ocular Surface Disease Index (OSDI)	4
Appendix 3	5
Devices for treating dry eye	5
Bottle / Device types for artificial tears	5
Appendix 4	6
Referral template for dry eye disease	6
Appendix 5	7
Request to GP for treatment for dry eye	7

Introduction

Dry eye is prevalent on a worldwide scale, and is one of the most common reasons for patients to attend eye care practitioners. [1] To the individual, it has a significant impact on quality of life, and at the societal level in economic terms, both with respect to the cost of treatment, and to lost productivity. Dry eye disease (DED) has been defined as follows:

"Dry eye is a multifactorial disease of the ocular surface characterized by a loss of homeostasis of the tear film, and accompanied by ocular symptoms, in which tear film instability and hyperosmolarity, ocular surface inflammation and damage, and neurosensory abnormalities play etiological roles." [2]

An extensive range of treatments are available for dry eye, although there are inherent difficulties in evaluating cost-effectiveness, due to:

- fluctuation of symptoms and signs
- variability in symptom reporting and assessment
- a rapidly-evolving market of available treatments
- a myriad of potential combinations and frequencies of treatment regimes
- · lack of clear endpoints to treatment

Dry Eye Working Group

The Scottish Dry Eye working group was established, with the following aims:

- identify current practice for the management of dry eye in community and secondary care
- review existing guidelines and highlight those aspects most applicable to local practices and patients
- determine areas of service provision that need the most improvement
- develop a clear pathway for patient referral to secondary care, and how best to guide treatment upon discharge back to community
- reach a consensus on diagnosis and treatment of DED at a national level
- devise a formulary that balances choice and cost

Invitations to participate in the working group were sent to the following groups:

- community lead optometrists, and those with a special interest in DED
- ophthalmologists specializing in cornea and anterior segment
- hospital pharmacists
- general practitioners and representatives from NHS Education for Scotland
- specialist nurses
- health board leads / managers

Meetings were hosted on 15/11/16 and 20/06/17. Preparatory and summative documentation was sent out to attendees, inviting comments and amendements to ensure that the documents reflected the consensus of the group.

Contributors to Dry Eye Working Group

A Agrawal
G Bruce
A Cowie
J Donaldson
C Ferrier
F Freeland
G Galloway
A Scott
K Smith
N Tint
P Wilson

Abbreviations

•	ADDE	Aqueous Deficient Dry Eye
•	DED	Dry Eye Disease
•	EDE	Evaporative Dry Eye
•	HES	Hospital Eye Service
•	IP	Independent Prescriber
•	MGD	Meibomian Gland Disease
•	OSDI	Ocular Surface Disease Index
•	PVA	Polyvinyl Alcohol
•	TFBUT	Tear Film Breakup Time

Overview of Guidelines

Dry eye	e assessment strategy	
	OSDI ¹	Evaluation at
	Background and risk factors	community
Step 1	Ocular signs - including Oxford grading system, TFBUT	optometrist - onward
	Eyelid disease	referral to IP optom
	Documentation of previous treatment strategies	as needed
If sympto	See referral letter	
	Evaluation as above	
Step 2	Consider auto-immune testing	Hospital-only
	Referral to Rheumatology	

Dry eye	treatment strategy ²					
	Education ³					
	Environmental measures					
	Diet / supplements					
Step 1	Systemic & topical medication review	Initiate in community				
	Lid hygiene / hot compresses					
	Ocular devices - patient to initiate at their discretion					
	Ocular lubricants - see formulary table below					
	Punctal occlusion (primarily for ADDE)					
	Topical steroids (aim for minimal duration / dose to achieve effect)					
Step 2 *	Topical antibiotics (Azithromycin)	Specialist dry-eye				
Step 2	Oral antibiotics (Doxycycline / Azithromycin)	practitioners				
	Contact lenses					
	Topical ciclosporin (initiate and monitor in hospital)					
Step 3	Serum tears, surgery, etc.	Hospital-only				

^{*}NB No order preference and not mutually exclusive

Proposed combined formulary								
Category	Product	List price*	Preservative-free ⁴	List price*				
Historic	Hypromellose	£1.21	Hypromellose ⁵	£5.72 (30 vials)				
1 st line	Carbomer / PVA	£0.68 / £1.93	Carbomer / PVA	£5.42 (30 vials)				
2 nd line	<u>-</u> 6		Carmellose, Hyaluronate	£7.49 / £10.80				
Ointments ⁷	-		Xailin Night / VitA-Pos / LacriLube	£2.49 / £2.75 / £3.88				
MGD	Systane Balance	£7.49	Optive Plus	£7.49				
Filamentary	iLube (<i>PoM</i>)	£15.68						
Severe DED			Topical ciclosporin (<i>PoM</i>)	£72.00				

^{*}Indicative list price per item. Subject to variation over time.

¹ Ocular Surface Disease Index, as a minimum baseline dataset

² Based on DEWS II treatment guideline

³ See IGA patient info booklet

 $^{^{\}rm 4}$ Consider preservative-free if > 4 drops applied per day, or if allergy to preservatives

⁵ Preservative-free hypromellose unlikely to be cost-effective

⁶ 2nd line agents will all be preservative-free

⁷ Ointments for use at night-time may be added as required; additionally during the day for more severe disease Decision to move from 1st to 2nd line and on is driven by no improvement in symptoms and /or signs after 6 - 8 weeks.

Dry Eye Assessment Strategy

Tools for evaluating dry eye

A range of tools were for evaluating the symptomatology of DED. These included:

- Undirected history & examination
- Ocular Surface Disease Index (OSDI) [3]
- Speed questionnaire [4]
- Symptom Assessment iN Dry Eye (SANDE) [5]
- McMonnies [6]

All of the above tests have been validated in comparative studies, and may be used for both clinical and research purposes. Of these tests, the group decided in favour of OSDI, as it is relatively simple to follow and score, and is already familiar to many practitioners working with DED patients.

Relevant medical history

In addition to the symptoms reported by the patient, it is important to record any relevant risk factors or precipitating factors. As a minimum dataset, this would include:

- Contact lenses
- Medications
- Arthritis / Sjögren's syndrome
- Thyroid disease
- Smoking
- Laser refractive surgery

A note should also be taken of any eye drops or other treatments for DED currently / previously used, and negative findings, both in history and examination.

Eye examination

A routine eye examination should be performed at every visit, with specific attention paid to any changes associated with DED. These include:

- Redness
- Blepharitis / eyelid disease
- Fluorescein staining & mucus filaments
- Tear film height & break-up time

A tool such as the Oxford grading scheme [7] may assist in more accurately recording objective signs at each visit. However, it is important to note that there is often discordance between the symptoms of dry eye and the observable signs.

Dry Eye Treatment Strategy

Patient-centred care

Patients must be empowered to trial a range of treatment options, and to settle on a combination that suits them as an individual. With clear explanations of the treatments available, the nature and purpose of treatment, and encouragement to adjust regimes pre-emptively, it is anticipated that most patients may be managed in community. It is often helpful to invest time with patients in these explanations, to help them manage dry eye disease more independently and to come to terms with it as a chronic condition.

A holistic approach

Treatment for dry entails more than a combination of lubricating eye drops. Beyond the general measures outlined in the above table, and the use of physical devices (Appendix 3), patients may benefit from support groups, online material and other educational resources.

Drop delivery

In addition to the multitude of preparations available for treating dry eye, many of these are supplied in a range of delivery systems, including traditional 5-10ml bottle (often with preservatives), single-use vials, pump-action and valve-based bottles, as well as gels and ointments (See Appendix 3). Patients - particularly those with arthritis - may find some of these quite difficult to use. Selection may ultimately depend upon the bottle type as much as the lubricant it contains.

Bibliography

- [1] J. Craig, J. Nelson, D. Azar, C. Belmonte and A. Bron, "TFOS DEWS II Report Executive Summary," *The Ocular Surface,* vol. 15, pp. 802-812, 2017.
- [2] J. Nelson, J. Craig, E. Akpek and A. Bron, "TFOS DEWS II Introduction," *The Ocular Surface*, vol. 15, pp. 269-275, 2017.
- [3] R. Schiffman, M. Christianson, G. Jacobsen, J. Hirsch and B. Reis, "Reliability and validity of the Ocular Surface Disease Index," *Arch Ophthalmol*, vol. 118, p. 615-21, 2000.
- [4] W. Ngo, P. Situ, N. Keir and D. Korb, "Psychometric Properties and Validation of the Standard Patient Evaluation of Eye Dryness Questionnaire," *Cornea*, vol. 32, pp. 1204-1210, 2013.
- [5] F. Amparo, D. Schaumberg and R. Dana, "Comparison of Two Questionnaires for Dry Eye Symptom Assessment: The Ocular Surface Disease Index and the Symptom Assessment iN Dry Eye," *Ophthalmology*, vol. 122, pp. 1498-1503, 2015.
- [6] C. McMonnies and A. Ho, "Responses to a dry eye questionnaire from a normal population.," *J Am Optom Assoc,* vol. 58, p. 588-91, 1987.
- [7] A. Bron, V. Evans and J. Smith, "Grading of corneal and conjunctival staining in the context of other dry eye tests," *Cornea,* vol. 22, pp. 640-50, 2003.

Appendix 1

Oxford Grading Scheme

Panel	Grade	Dot count per sector
A	0	1
B (1) (1) (1) (1) (1)	-	10
	II	32
	III	100
E	IV	316
>E	V	>316

Appendix 2

Ocular Surface Disease Index (OSDI)

Ocular Surface Disea	se i	nae	ЭX (05	(וט			
	All the time (4)	Most of the time (3)	Half of the time (2)	Some of the time (1)	None of the time (0)	N/A		
Have you experienced any of the week?	of the	e follo	wing	durin	g the	last		
1. Eyes that are sensitive to light?								
2. Eyes that feel gritty?								
3. Painful or sore eyes?								
4. Blurred vision?								
5. Poor vision?								
Subtotal for section 1	(max 20)							
Have problems with your eyes limit the following during the last week?	ed yc	ս in բ	perfor	ming	any	of		
6. Reading?								
7. Driving at night?								
8. Working with a computer?								
9. Watching TV?								
Subtotal for section 2	(max	(16)						
Have your eyes felt uncomfortable situations during the last week?	in an	y of th	ne fol	lowin	g			
10. Windy conditions?								
11. Places with very low humidity?								
12. Areas that are air conditioned?								
Subtotal for section 3	(max	(12)						
Add subtotals (= "D")	(max	(48)						
No. questions answered (= "E")	(max	(12)						
OSDI score = (D ÷ E) x 25 (max 100)								

Appendix 3

Devices for treating dry eye

Treatment	Details	Examples	Guide price approx								
Tear retention											
Punctal plugs	Absorbable plugs		£6.20 / pair								
i unctai piugs	Permanent plugs		£25.67 / pair								
Moisture chamber spectacles			£45 - £115								
Contact lenses	Silicone hydrogel lenses		£4.05 / pair								
Contact lenses	Scleral lenses		£120/ pair								
	Meibomian gland dysfun	ction									
Nutritional supplements	Essential fatty acids	Omega 3	£18.93 / mth								
"At home" heat treatments	Warm compresses / eye masks		£3.33 - £30 / mth								
	Goggles	Blephasteam	£175.40								
"In office" heat treatments	Thermal pulsation treatment / pulsed light therapy	Lipiflow, E-eye	Cost to pt £700								
	Blepharitis										
Eye lid hygiene	Lid wipes and cleaning products		£7 - £8 / mth								
"In office" eyelid cleaning		Bleph-ex	Machine £835 Disposable tips £12 / use								
Demodex blepharitis	Lid wipes with tea tree oil	Cliradex	£30 / mth								

Bottle / Device types for artificial tears

	Artificial Tear Product Examples										
Bottle / Device	Standard bottle	Pump-action / valve	Single-use vial	Gel tube							
Carbomer	-	-	Carbomer 980 SDU Viscotears SDU	Carbomer 980 Viscotears Xailin Gel							
Carmellose	Lumecare Optive Refresh Tears Plus	-	Carmize Celluvisc Xailin Fresh	-							
Hyaluronate	Blink Intensive Xailin HA	Clinitas Soothe Multi Hylo-Forte Vismed Gel Multi	Vismed Gel SDU	-							

Appendix 4

Referral template for dry eye disease

Direc	t R	efe	erra	al ⁻	Γo Ι	Hos	spita	al Ey	/e	Ser	vice				
Dry E	Eye														
												Urg	geno	y of ref	erral
HOCDITAL		- A T I C	NI CC	NDE.				ш) CDI	FAI					
HOSPITAI					nt Fore	name		нс	SPI	Title	Optometr	iet Det	aile		
i atient ot	arriarri		──	atic	iit i ore	ilallik				TILLE	Optometi	ist Det	lans		
DOB				СНІ				GEND	ER						
Address					-			-							
Postcode			1	Tel No	•										
Ethnicity			- 1-												
Location C				HCP (Code			.			Date of Re	ferral			
Patient Hi	story 8	& Deta	ails					Patient		•					
								If Yes?			ce at HES				
								If Yes?							
											sonnel, Imr	nediate	e fan	nilies and	d veterans
								Transla					- 10111		
								guage							
Ocular Su	ırface l	Disea	se Ind	dex (OSDI)		Scor	e each item 0-4					Sum		
Light sens			Gritt			Pair	ain Blurred				Poor vision				
Reading			Driv	ing		Con	Computer TV								
Discomfo	rt whe	n:	Win	dy		Dry	conditio	ons Air con							
OSDI Sco	_	-	25							Subto					
= (r	nax 10									Num	ber of ques				<u></u>
Risk facto	ors	- 1		_				hritis				Sjögren's syndrome			
						_ <u> </u>		noking ti depre				Laser eye surgery Beta-blockers ("-olol")			$-\frac{\sqcup}{\sqcap}$
Medicatio	ns							-	ti-depressants retics (-"azide")			Anti-psychotics ("-azine")			
			Othe												, _
Eye drops											Stage 1		1 1	omplian	
including											exhaust	ed		onfirmed	<u>. </u>
	- 1	Right	(O E)				Ocular Examination Oxford Grading Scheme			Left					
		((0-5)			+		yelid dis						(0-5)	
							<u></u> ;	yena ais	case	•					
Visio			Sph		Cyl		Axis		VA	١	PH VA		Add	t l	NVA
Righ		_				\perp									
Left		Lofe	-12		_				,						
GP inform				L				GF		ctice					
Patient given dry eye leaflet?			er: L				G	га	CHCE						

Appendix 5

Re

		Date_	
Patient details Surname: First name: DOB / CHI: General Practice:	Optometrist detai	amp)	
ear Doctor, our patient has been diagnosed with dry eye (REA	D code F4F14)		
would be grateful if the following could be added to ight / Left / Either* eye:	,	iption, to be u	
Substance	P/F?	Cost ¹	Frequency X times per day or "PRN
Car	rbomer gel		
E.g. Carbomer, Clinitas, Gel Tears, Viscotears		£0.68	
Poly-Viny	yl Alcohol (PVA)		
E.g. Blink revitalizing, Liquifilm, Sno Tears		£1.93	
Ca	armellose		
E.g. Celluvisc, Optive, Refresh Plus	✓	£4.80	
Ну	aluronate		
E.g. Hycosan, Hylo-Forte, Vismed, Xailin HA	✓	£7.50	
Comb	ination drops		
E.g. Optive Fusion, ² Hylo Dual, ³ Thealoz Duo ⁴	✓	£9.80	
Paraffin oil⁵ (Eye ointr	ments, usually app	lied nocte)	
E.g. Lacri-lube, Vita-Pos, Xailin Night, Hycosan Ni	ght ✓	£2.75	
	Other		
Other (specify):			
F = Preservative-free			
Indicative price within this category Carmellose and Hyaluronate Hyaluronate and Ectoin Trehalose and Hyaluronate All contain Lanolin			
ollow-up for your patient has been arranged as follo	ows:		

Follow-up with optometrist Referred to / already in hospital eye service

No follow-up is required